Basiliximab
Immunosuppression
Shanghai Jiao Tong University School of Medicinemonoclonal_antibodyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Immunosuppression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ZINC SULFATE Fakultas Kedokteran Universitas Indonesia | Phase 4 | BB |
Hydroxyurea Fakultas Kedokteran Universitas Indonesia | Phase 4 | BB |
Folic Acid Fakultas Kedokteran Universitas Indonesia | Phase 4 | BB |
CYCLOSPORIN A West China Hospital | Phase 4 | B |
Monomethyl Fumarate West China Hospital | Phase 4 | B |
Histamine Sahlgrenska University Hospital | Phase 2 | CCC |
TACROLIMUS Shanghai Jiao Tong University School of Medicine | N/A | D |
Same molecule, other indications
Basiliximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →